Clovis Oncology (CLVS) Misses Q4 EPS by 18c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Clovis Oncology (CLVS) Misses Q4 EPS by 18c

Clovis Oncology Announces 2016 Operating Results

February 22, 2017 4:05 PM EST

Rubraca (rucaparib) approved and launched in the U.S. on December 19, 2016 for the treatment of advanced BRCA-mutant ovarian cancer $266.2M in cash, cash equivalents and available for sale securities at December 31, 2016 $487.4M in adjusted cash, cash equivalents and available for sale securities at December 31, 2016 as adjusted for the January 2017 financing proceeds of $221.2 million Rucaparib MAA submission accepted and under review; CHMP opinion anticipated Q4 2017 Establishing EU commercial organization Data from ARIEL3 pivotal rucaparib maintenance study expected... More